Literature DB >> 19962742

Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid.

Jeffrey B Travers1, Amal Kozman, Nico Mousdicas, Chandan Saha, Megan Landis, Mohammed Al-Hassani, Weiguo Yao, Yongxue Yao, Ann-Marie Hyatt, Michael P Sheehan, Anita N Haggstrom, Mark H Kaplan.   

Abstract

BACKGROUND: Bacterial infection with Staphylococcus aureus is a known trigger for worsening of atopic dermatitis (AD); the exact mechanisms by which bacterial infection worsens dermatitis are unknown.
OBJECTIVE: We sought to characterize the amounts of the biologically active bacterial lipoprotein lipoteichoic acid (LTA) in infected AD lesions.
METHODS: Eighty-nine children with clinically impetiginized lesions of AD were enrolled in this study. A lesion was graded clinically by using the Eczema Area and Severity Index (EASI), wash fluid obtained from the lesion for quantitative bacterial culture, and measurement of LTA and cytokines. The staphylococcal isolate was tested for antibiotic susceptibilities. The patients were treated with a regimen that included topical corticosteroids and systemic antibiotics, and the lesion was reanalyzed after 2 weeks.
RESULTS: S aureus was identified in 79 of 89 children enrolled in the study. The bacterial colony-forming unit (CFU) counts correlated with the EASI lesional score (P = .04). LTA levels as high as 9.8 mug/mL were measured in the wash fluid samples, and the amounts correlated with the lesional EASI scores (P = .01) and S aureus CFU (P < .001). Approximately 30% of clinically impetiginized AD lesions contained greater than 1 mug/mL LTA, amounts that exert effects on various cell types in vitro. Moreover, injection of skin tissue ex vivo with amounts of LTA found in AD lesions resulted in epidermal cytokine gene expression.
CONCLUSION: Pharmacologic levels of LTA are found in many infected atopic dermatitis lesions. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962742      PMCID: PMC2813977          DOI: 10.1016/j.jaci.2009.09.052

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  33 in total

1.  Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells.

Authors:  Hassan Lemjabbar; Carol Basbaum
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

2.  The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2.

Authors:  K S Michelsen; A Aicher; M Mohaupt; T Hartung; S Dimmeler; C J Kirschning; R R Schumann
Journal:  J Biol Chem       Date:  2001-04-20       Impact factor: 5.157

3.  Lipoteichoic acid from Staphylococcus aureus induces Th2-prone dermatitis in mice sensitized percutaneously with an allergen.

Authors:  K Matsui; A Nishikawa
Journal:  Clin Exp Allergy       Date:  2002-05       Impact factor: 5.018

4.  Endogenous antimicrobial peptides and skin infections in atopic dermatitis.

Authors:  Peck Y Ong; Takaaki Ohtake; Corinne Brandt; Ian Strickland; Mark Boguniewicz; Tomas Ganz; Richard L Gallo; Donald Y M Leung
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

Review 5.  Tlr4: central component of the sole mammalian LPS sensor.

Authors:  B Beutler
Journal:  Curr Opin Immunol       Date:  2000-02       Impact factor: 7.486

6.  Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection.

Authors:  O Takeuchi; K Hoshino; S Akira
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

7.  A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection.

Authors:  E Lorenz; J P Mira; K L Cornish; N C Arbour; D A Schwartz
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

8.  Cell wall components of Staphylococcus aureus induce interleukin-5 production in patients with atopic dermatitis.

Authors:  K Matsui; R Motohashi; A Nishikawa
Journal:  J Interferon Cytokine Res       Date:  2000-03       Impact factor: 2.607

9.  Effects of staphylococci on cytokine production from human keratinocytes.

Authors:  T Sasaki; R Kano; H Sato; Y Nakamura; S Watanabe; A Hasegawa
Journal:  Br J Dermatol       Date:  2003-01       Impact factor: 9.302

10.  The Toll-like receptor 2 R753Q mutation modifies cytokine production and Toll-like receptor expression in atopic dermatitis.

Authors:  Salima Mrabet-Dahbi; Alexander H Dalpke; Margarete Niebuhr; Markus Frey; Christian Draing; Stephanie Brand; Klaus Heeg; Thomas Werfel; Harald Renz
Journal:  J Allergy Clin Immunol       Date:  2008-01-30       Impact factor: 10.793

View more
  23 in total

Review 1.  Microbial ecology of the skin in the era of metagenomics and molecular microbiology.

Authors:  Geoffrey D Hannigan; Elizabeth A Grice
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

2.  Enhanced Platelet-Activating Factor Synthesis Facilitates Acute and Delayed Effects of Ethanol-Intoxicated Thermal Burn Injury.

Authors:  Kathleen A Harrison; Eric Romer; Jonathan Weyerbacher; Jesus A Ocana; Ravi P Sahu; Robert C Murphy; Lisa E Kelly; Townsend A Smith; Christine M Rapp; Christina Borchers; David R Cool; Gengxin Li; Richard Simman; Jeffrey B Travers
Journal:  J Invest Dermatol       Date:  2018-05-30       Impact factor: 8.551

3.  Identification of staphylococcal protein A in infected atopic dermatitis lesions.

Authors:  Yongxue Yao; Amal Kozman; Mohammed Al-Hassani; Chandan K Saha; Qiaofang Yi; Weiguo Yao; Nico Mousdicas; Mark H Kaplan; Jeffrey B Travers
Journal:  J Invest Dermatol       Date:  2010-06-03       Impact factor: 8.551

4.  Staphlyococcus aureus phenol-soluble modulins stimulate the release of proinflammatory cytokines from keratinocytes and are required for induction of skin inflammation.

Authors:  Adnan K Syed; Tamra J Reed; Kaitlyn L Clark; Blaise R Boles; J Michelle Kahlenberg
Journal:  Infect Immun       Date:  2015-06-15       Impact factor: 3.441

5.  Treatment outcomes of secondarily impetiginized pediatric atopic dermatitis lesions and the role of oral antibiotics.

Authors:  Jeffrey B Travers; Amal Kozman; Yongxue Yao; Wenyu Ming; Weiguo Yao; Mathew J Turner; Mark H Kaplan; Nico Mousdicas; Anita N Haggstrom; Chandan Saha
Journal:  Pediatr Dermatol       Date:  2011-12-09       Impact factor: 1.588

6.  Altered cytokine production by dendritic cells from infants with atopic dermatitis.

Authors:  Weiguo Yao; JiHoon Chang; Sarita Sehra; Jeffrey B Travers; Cheong-Hee Chang; Robert S Tepper; Mark H Kaplan
Journal:  Clin Immunol       Date:  2010-09-29       Impact factor: 3.969

7.  Dendritic cells produce inflammatory cytokines in response to bacterial products from Staphylococcus aureus-infected atopic dermatitis lesions.

Authors:  Timothy Voorhees; Jihoon Chang; Yongxue Yao; Mark H Kaplan; Cheong-Hee Chang; Jeffrey B Travers
Journal:  Cell Immunol       Date:  2010-10-30       Impact factor: 4.868

8.  Encoding a superantigen by Staphylococcus aureus does not affect clinical characteristics of infected atopic dermatitis lesions.

Authors:  A Kozman; Y Yao; P Bina; C Saha; W Yao; M H Kaplan; J B Travers
Journal:  Br J Dermatol       Date:  2010-12       Impact factor: 9.302

9.  NOD2 and TLR2 ligands trigger the activation of basophils and eosinophils by interacting with dermal fibroblasts in atopic dermatitis-like skin inflammation.

Authors:  Delong Jiao; Chun-Kwok Wong; Huai-Na Qiu; Jie Dong; Zhe Cai; Man Chu; Kam-Lun Hon; Miranda Sin-Man Tsang; Christopher Wai-Kei Lam
Journal:  Cell Mol Immunol       Date:  2015-09-21       Impact factor: 11.530

Review 10.  The role of innate immune signaling in the pathogenesis of atopic dermatitis and consequences for treatments.

Authors:  Yuliya Skabytska; Susanne Kaesler; Thomas Volz; Tilo Biedermann
Journal:  Semin Immunopathol       Date:  2015-11-16       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.